Accelerometer-based measures in Friedreich ataxia: a longitudinal study on real-life activity.

Friedreich ataxia activity monitor digital measure outcome measures wearable sensors

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 22 11 2023
accepted: 28 02 2024
medline: 3 4 2024
pubmed: 3 4 2024
entrez: 3 4 2024
Statut: epublish

Résumé

Quantitative measurement of physical activity may complement neurological evaluation and provide valuable information on patients' daily life. We evaluated longitudinal changes of physical activity in patients with Friedreich ataxia (FRDA) using remote monitoring with wearable sensors. We performed an observational study in 26 adult patients with FRDA and 13 age-sex matched healthy controls (CTR). Participants were asked to wear two wearable sensors, at non-dominant wrist and at waist, for 7 days during waking hours. Evaluations were performed at baseline and at 1-year follow-up. We analysed the percentage of time spent in sedentary or physical activities, the Vector Magnitude on the 3 axes (VM3), and average number of steps/min. Study participants were also evaluated with ataxia clinical scales and functional tests for upper limbs dexterity and walking capability. Baseline data showed that patients had an overall reduced level of physical activity as compared to CTR. Accelerometer-based measures were highly correlated with clinical scales and disease duration in FRDA. Significantly changes from baseline to l-year follow-up were observed in patients for the following measures: (i) VM3; (ii) percentage of sedentary and light activity, and (iii) percentage of Moderate-Vigorous Physical Activity (MVPA). Reduction in physical activity corresponded to worsening in gait score of the Scale for Assessment and Rating of Ataxia. Real-life activity monitoring is feasible and well tolerated by patients. Accelerometer-based measures can quantify disease progression in FRDA over 1 year, providing objective information about patient's motor activities and supporting the usefulness of these data as complementary outcome measure in interventional trials.

Identifiants

pubmed: 38567352
doi: 10.3389/fphar.2024.1342965
pii: 1342965
pmc: PMC10985256
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1342965

Informations de copyright

Copyright © 2024 Fichera, Nanetti, Monelli, Castaldo, Marchini, Neri, Vukaj, Marzorati, Porcelli and Mariotti.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Mario Fichera (M)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Lorenzo Nanetti (L)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Alessia Monelli (A)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Anna Castaldo (A)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Gloria Marchini (G)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Marianna Neri (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Xhuljano Vukaj (X)

Institute of Biomedical Technologies, National Research Council, Segrate, Italy.

Mauro Marzorati (M)

Institute of Biomedical Technologies, National Research Council, Segrate, Italy.

Simone Porcelli (S)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Caterina Mariotti (C)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Classifications MeSH